BILLERICA, Massachusetts, October 6 /PRNewswire/ --

- Novel technology opens the door to the understanding of and possible treatments for obesity, diabetes, ageing and cancer

Seahorse Bioscience today announced the release of the first ever analytical instrument for the kinetic measurement of mitochondrial oxygen consumption and cytoplasmic glycolysis in cells in a 96 well microplate. For the past 75 years tools for measuring cellular bioenergetics have been relatively unchanged since Warburg designed the Warburg Apparatus in 1932 and Leland Clark invented the Clark oxygen electrode in 1959.

MONTREAL, October 6 /PRNewswire/ --

Caprion Proteomics Inc. announced today that it has been awarded a US$12.9 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the US National Institutes of Health, to carry out Biodefense research in the area of infectious disease biomarkers.

LOS ANGELES, October 6 /PRNewswire/ --

- The new facility, based in Los Angeles, California is anticipated to be operational in 2013 and will expand the Company's ability to supply its new generation of intravenous immune globulin into the foreseeable future.

PASADENA, California and LONDON, October 6 /PRNewswire/ -- A staggering 93% of Brits don't believe that a scientific formula can help them find love. But, this thinking is set to be turned on its head with the UK launch of the highly successful US singles matching service, eHarmony.

Unlike other dating sites - where members post a picture and a short biography, before browsing the profiles of other users - eHarmony uses an advanced web-based "Compatibility Matching System" to present users with compatible matches, based on key dimensions of their personality. Over half (56%) surveyed said that compatibility is key in a potential partner.

NEW YORK, October 6 /PRNewswire/ -- In the news release, "SunGard Wins Special Recognition for SOA Achievements" issued on 6 Oct 2008 13:30 GMT, by SunGard over PR Newswire, we are advised by a representative of the company that the second paragraph, last sentence should read, "For example, SunGard's Ambit Liquidity Manager combines cash management and reconciliation components based on existing solutions for an integrated, real-time view of liquidity and risk." rather than, "For example, SunGard's Ambit Liquidity Manager combines cash management and reconciliation components from SunGard's AvantGard and STeP solutions." as originally issued inadvertently. Complete, corrected release follows:

RICHMOND, England, October 6 /PRNewswire/ -- IDOX plc (LON: IDOX) the specialist information and knowledge management company, has chosen Increase CRM, to implement and host a Microsoft Dynamics CRM solution.

In the first phase of the project, CRM experts Increase will provide IDOX with Microsoft SureStep(R) implementation services and a Hosted Microsoft Dynamics CRM 4.0 platform to streamline sales order processing and improve sales forecasting accuracy.

NEW YORK, October 6 /PRNewswire/ --

SunGard has been recognized by the SOA Consortium and CIO Magazine for having successfully delivered business value through its Common Services Architecture (CSA), a vendor-agnostic service oriented architecture (SOA) based on mainstream open standards. The SOA Case Study Competition determined that SunGard's CSA has helped to enhance customer satisfaction by facilitating a higher volume of software solutions delivered, greater efficiencies in delivering those solutions, and increased compatibility for integrating with customers' SOA environments.

SCHLIEREN, Switzerland, LAUSANNE, Switzerland and SAN DIEGO, October 6 /PRNewswire/ --

Oncalis AG (Oncalis), a privately-owned Swiss biotechnology company, and ChemDiv Inc. (ChemDiv), a privately-owned, California-based discovery services company announced that they entered into an exclusive agreement for a license to Oncalis a family of PI3K inhibitors. ONC-201, the first development candidate from this family, is a potent and selective orally-bioavailable member of a new class of drugs targeting PI3-kinase. ONC-201 has demonstrated highly promising anti-cancer efficacy in pre-clinical cancer models.

SANTA CLARA, California, October 6 /PRNewswire/ --

SAN JOSE, California, October 6 /PRNewswire/ --

Atmel(R) Corporation (Nasdaq: ATML) has received a Readers Tech Choice award from eg3 for its embedded development kit for CryptoController(TM) (http://www.atmel.com/products/embedded/default.asp), Atmel's Trusted Platform Module (TPM) for non-PC, embedded applications. This kit also earned eg3's Editors Tech Choice Award. eg3.com is the leading non-biased news source for embedded systems, dsp, real-time/rtos, chip design, FPGA, and boards on the internet.